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Abstract: In this study, (E)-9-ethyl-N-((1,3-diphenyl-1H-pyrazol-4-ylmethylene)-9H-carbazol-3-amine (3a–f) and 1-(9-ethyl-9H-carbazol-6-yl)-3-
phenylthiourea (5a–f) derivatives were synthesized and their in vitro antimicrobial and antimalarial activities were evaluated. The structures of 
the synthesized compounds were elucidated and confirmed by using IR, 1H NMR, 13C NMR, and mass spectra. 
 






HE carbazole skeleton is a key structural motif posses-
ses desirable electronic and charge-transport proper-
ties as well as large π conjugated system. Due to this, the 
various functional groups are easily introduced into the 
structurally rigid carbazolyl ring. These characteristics 
result in the extensive potential applications of carbazole-
based derivatives in the field of medicinal,[1–5] organic[6,7] 
and material chemistry.[8,9]  
 Aminocarbazoles and its derivatives have gained 
much attraction due to their prominent biological 
activities.[10–15] They have been identified as Bcl-2 protein 
inhibitors[16] NPY5 antagonists[17] and anion receptors.[18] 
They are also useful intermediates for the synthesis of 
various amino derivatives, dyes and pigments, stabilizers 
for polymers, pesticides, photographic materials and 
diagnostic reagents in cytochemical studies.[19]  
 Pyrazole derivatives represent one of the most 
active class of compounds and possess a wide spectrum of 
biological activities.[20–25] Schiff bases have also been shown 
a broad range of biological activities, including antifungal, 
antibacterial, antimalarial, anti-inflammatory, antiviral, and 
antipyretic properties.[26,27] The new tacrine carbazole 
hybrids having imines moiety reported to possess 
multifunctional agents for the treatment of AD and potent 
activity against AChE inhibitory and antioxidant action.[28,29] 
Although some drugs containing pyrazole and Schiff bases 
exhibit antiviral activities,[30,31] carbazole based diarylthiourea, 
pyridopyrimidine-substituted urea and thiourea derivatives 
have been reported as potent anticancer agents [32] and 
polyphenol oxidase inhibitors.[33] Inhibitory activities of 
carbazole-linked urea and thiourea derivatives on lipo-
polysaccharide-induced NO production have been also 
reported.[34] Also p-nitrodiarylthiourea derivative contains 
carbazole core have been evaluated on breast (MCF-7,  
T-47D, MDA-MB-453) and prostate (DU-145, PC-3, LNCaP) 
cancer cell lines.[35] 
 Based on the above information, we inferred that 
carbazole frame linked at 4-position in the pyrazole ring 
and aryl thiourea core could lead to significant increase in 
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RESULTS AND DISCUSSION 
Chemistry 
The synthetic route is shown in schemes 1 and 2. Carbazole 
Schiff bases (3a–f) were prepared in accordance with the 
literature procedure,[36] starting from the condensation of 
9-ethyl-9H-carbazol-3-amine 1 with substituted 1,3-diaryl 
pyrazole aldehyde 2 in ethanol and a catalytic amount of 
glacial acetic acid. The substituted 1,3-diaryl pyrazole 
aldehydes were synthesized by the well-known Vilsmeier-
Haack formylation reaction.[37] Carbazole-based thiourea 
derivatives (5a–f) were synthesized by the reaction of  
9-ethyl-9H-carbazol-3-amine 1 with various substituted 
phenylisothiocynate 4 in ethanol. The synthesis of com-
pound 5e has been previously reported.[38] 
 The formation of carbazole linked Schiff bases (3a–f) 
were confirmed by various spectral methods. The FT-IR spectra 
clearly indicates that the IR band at 1596–1599 cm–1 
appeared due to the typical azomethine (–CH=N) group 
and, thus, confirmed the formation of carbazole Schiff 
bases. Also the bands due to –NH2 group of N-alkylated 
carbazolyl amine at 3390 cm–1 and the carbonyl (C=O) 
group of pyrazole aldehyde at 1890 cm–1 completely disap-
peared. 
 In 1H NMR spectra, aldehyde (CHO) and NH2 proton 
of amine peaks expected at δ 9.89 and 6.55 disappeared. In 
the 1H NMR spectra of representative compound 3f, one 
new singlet that appeared at δ 9.18 due to the CH=N of 
azomethine confirmed the formation of Schiff bases. 
Similarly, in the 13C NMR, carbonyl group (CHO) expected at 
δ 190 disappeared. The formation of Schiff base was 
confirmed by observing (–CH=N) carbon atom in the range 
of δ 152.10–162.56 for azomethine. The mass spectrum of 
3f displayed a molecular ion peak at m/z 447.16 due to 
(M+1)+ mode. Also the high resolution mass spectrum 
(HRMS) of compound 3f showed a molecular ion peak at 
m/z 447.1646, which confirmed the formation of 
compound 3f.  
 The thiourea derivatives (5a–f) were confirmed by 
the absence of characteristic IR absorption band at 2000–
2200 cm−1 (N=C=S group). The IR band at 3100-3370 cm–1 
appeared due to NH stretching, while the characteristic 
region of the high frequency for thiocarbonyl (C=S) in the 
aromatics thioureas appeared at 1530-1549 cm−1. For 
example, the 1H NMR spectrum of compound 5a showed 
two characteristic downfield singlets at δ 9.65 and 9.81 
assigned to the protons of two NH groups, while in 13C NMR 
spectrum, the peak due to thiocarbonyl group in thiourea 
moiety of 5a was observed at δ 180.76 because thiocarbonyl 
 












Scheme 1. Synthetic route of carbazole linked pyrazole Schiff base (3a–f) 
 




 G. D. SHIROLE et al.: Synthesis and Biological Assessment of Carbazole Derivatives 141 
 




group have a greater magnetic anisotropy compared to the 
carbonyl group. Furthermore, the mass spectrum shows 
the molecular ion peak at (m/z) 346.13 (M+H)+ which 
confirmed the formation of 5a. 
Antibacterial and Antifungal Evaluations 
The antimicrobial activity of the synthesized compounds  
3 and 5 was evaluated against two gram-negative (E. coli,  
P. mirabilis), two gram-positive (S. faecalis, B. subtilis) 
bacterial strains, and three (C. albicans, P. chrysogenum,  
A. niger) fungal strains using streptomycin and fluconazole 
as a standard drugs. The minimal inhibitory concentration 
(MIC) values of carbazole linked pyrazole Schiff base 
derivatives were presented in Table 1. 
 It was found that among the 3a–f derivatives 3b, 3c, 
3d and 3f showed stronger antibacterial efficacies and 
broader bioactive spectrum against E. coli, S. faecalis, and 
B. subtilis with the MIC values in the range of 10.5–15.5 
µg/mL comparable to that of the positive control. 
Compounds 3a and 3e exhibited moderate to good 
inhibitory activities (20 and 25 µg/mL) against all tested 
bacterial strains. Furthermore, compounds 3b, 3c and 3f 
showed a broad spectrum of antifungal activities (10.5–
15.5 µg/mL) against C. albicans and A. niger as compared 
with standard drug fluconazole, while compounds 3a, 3d, 
3e and 3f showed satisfactory activities (20–25 µg/mL). 
 MIC values of carbazole based thiourea derivatives 
(5a–f) as shown in Table 2 revealed that compounds 5b and 
5e exhibited highest inhibition activities (8.5–12.5 µg/mL) 
against E. coli, S. faecalis and B. subtilis bacterial strains. 
Compounds 5b, 5c, 5d and 5e displayed remarkable 
inhibition activities with a MIC value ranging from 10.5 to 
12.5 µg/mL against P. chrysogenum fungal strains, while 
compounds 5a-f showed to be less active on C. albicans and 
A. niger fungal strains relative to standard drug fluconazole. 
Most of the compounds 3 and 5 did not inhibit the growth 
of P. mirabilis bacterial strain satisfactorily, as compared 
with positive control streptomycin.  
Table 1. Antimicrobial activities of the synthesized compounds 3a-f against pathological organisms expressed as minimal 



















3a 25 25 25 20 20 25 25 
3b 10.5 20 11.5 10.5 12.5 20.5 13.5 
3c 12.5 25 15.5 13.5 14.5 20 15.5 
3d 15 25 20 15.5 20 15.5 15 
3e 20.5 25 20 20.5 20 20.5 20 
3f 11.5 25 14.5 14.5 10.5 20 15.5 
Streptomycin 6.25 6.25 6.25 6.25 — — — 
Fluconazole — — — — 6.25 6.25 6.25 
 
Table 2. Antimicrobial activities of the synthesized compounds 5a–f against pathological organisms expressed as minimal 



















5a 20 25 25 20 20 20 25 
5b 9.5 25 10.5 12.5 25 10.5 20 
5c 10 20 12.5 20 20 12.5 20 
5d 15 25 15.5 20 25 12.5 25 
5e 8.5 20 10.5 12.5 20 11.5 20 
5f 20 25 20 25 20 20 25 
Streptomycin 6.25 6.25 6.25 6.25 — — — 
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The synthesized compounds 3 and 5 were also screened for 
their in vitro antimalarial activity against Plasmodium 
falciparum strain using chloroquine and quinine as 
reference drugs. The mean IC50 (µg/mL) values of test 
compounds against the test microbe are presented in Table 
3. The results revealed that the majority of the synthesized 
compounds showed significant degrees of inhibition 
against P. falciparum as compared with standard drugs.  
 Among the carbazole linked pyrazole Schiff bases 
(3a–f), compound 3b with fluorine substituent attached 
exhibited a respectable antimalarial spectrum with IC50 
value of 0.90 µg/mL, as compared with compounds 3a, 3c, 
3d and 3e and standard drug quinine. Compounds 3a, 3c, 
3d and 3e exhibited satisfactory antimalarial activity with 
IC50 value ranging from 1.00 to 1.55 µg/mL. Compound 3f 
with thiophene substituent showed considerable inhibition 
activities with IC50 value of 0.95 µg/mL. In case of carbazole 
bearing diarylthiourea derivatives (5a–f), 5b and 5e showed 
the strong growth inhibition activities (with IC50 values of 
0.95 and 1.00 µg/mL) as compared with standard drug 
quinine, while compounds 5a, 5c, 5d and 5f showed 
moderate to good inhibition activities against P. falciparum 
comparable to that of the reference compounds. 
 
CONCLUSIONS 
To summarize, syntheses of a series of (E)-9-ethyl-N-((1,3-
diphenyl-1H-pyrazol-4-yl)methylene)-9H-carbazol-3-amine 
(3a-f) and 1-(9-ethyl-9H-carbazol-6-yl)-3-phenylthiourea 
(5a-f) were carried out in which some electron with-
drawing, donating as well as bulky functional groups were 
introduced to the phenyl ring. Also, it is known that the 
presence of halides (F, Cl, Br) increases the lipophilic 
properties of the compounds. Antimicrobial study of the 
synthesized compounds indicated that some of the 
compounds displayed moderate to potent antibacterial 
and antifungal activities which will be further helpful for the 
development of new antimicrobial compounds. As struc-
ture-activity relationship (SAR) study of all the compounds 
was taken into account (Figure 1), it was observed that the 
Table 3. Antimalarial activities of the synthesized com-
pounds 3a–f and 5a–f against P. falciparum expressed as IC50 
(μg/mL) 
 P. falciparum  P. falciparum 
Compd. No. IC50 (μg/mL) Compd. No. IC50 (μg/mL) 
3a 1.50 5a 1.65 
3b 0.90 5b 0.95 
3c 1.00 5c 1.10 
3d 1.15 5d 1.25 
3e 1.55 5e 1.00 
3f 0.95 5f 1.75 
Quinine 0.268 — 0.268 
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combination of carbazole moiety to various pyrazole 
aldehyde and substituted phenylisothiocynate in new 
derivatives caused increased activities against most of the 
tested organisms. The results also suggested that the 
antimicrobial activities of the carbazole derivatives were 
influenced by the aromatic substituent. Compounds with 
electron-withdrawing substituent 3b, 3c, 3d, 5b, 5c, 5d and 
5e in the phenyl ring were more potent against most of the 
tested microorganisms than compounds 3e and 5f with 
electron-donating groups. Furthermore, compounds 3a 
and 5a without substituent in the phenyl ring showed 
satisfactory activities against all tested bacterial and fungal 
strains. It was observed that, the sulphur containing Schiff 
base and diarylthiourea derivatives showed remarkably 
increments in the antibacterial, antifungal and antimalarial 
activities. In case of diarylthiourea derivatives, compound 
5b with fluorine substituent increased the antimalarial 
activity of the molecule, as compared with compounds 
containing chlorine, bromine and methyl groups. High 
potency and promising antimicrobial activity of the 
synthesized compounds 3a–f and 5a–f suggest that these 
compounds could serve as good leads for further 
optimization and development. 
 
EXPERIMENTAL 
The recorded melting points were determined in an open 
capillary and are uncorrected. IR spectra were recorded on 
Perkin Elmer Fourier-transform infrared (FTIR) spectro-
photometer with ATR. The 1H NMR and 13C NMR spectra 
were recorded on a Bruker Avance II (500 MHz) and Bruker 
(125 MHz) spectrometer respectively, using TMS as internal 
standard. Mass spectra were recorded on a Waters Q-TOF 
micromass spectrophotometer. The thin layer chromato-
graphy (TLC) was carried out on precoated silica gel 
aluminum plates to check compounds purity. The starting 
materials 9-ethyl-9H-carbazol-3-amine and substituted 
phenylisothiocynate of Sigma Aldrich make were 
purchased from local chemical providers. The antimicrobial 
activity was evaluated by the agar well diffusion method.[39] 
The in vitro antimalarial assay was carried out in 96 well 
plates according to the micro assay protocol of Rieckmann, 
and co-workers with minor modifications.[40] 
Minimal Inhibitory Concentration (MIC) 
Measurement 
The potato dextrose broths used for microorganism 
susceptibility tests in nutrient media for the determination 
of MIC. The tested compound stock 1000 µg/mL solutions, 
Streptomycin and Fluconazole were prepared in DMSO 
followed by dilutions to 100–6.25 µg/mL concentrations. 
Inoculated microorganism suspensions were incubated at 
37 °C for 1–5 days for MIC determination.  
General Procedure for the Synthesis of 
Compounds 3a–f 
9-Ethyl-9H-carbazol-3-amine 1 (1.5 mmol) and substituted 
1,3-diphenyl-1H-pyrazole-4-carbaldehyde 2 (1.5 mmol) were 
dissolved in ethanol (10 mL) and refluxed in reaction flask 
for 1h. After that, 2-3 drops of acetic acid was added to 
solvent as a catalyst. As a result of condensation reaction 
reddish brown color was observed. After completion of the 
reaction (monitored by TLC), the reaction mixture was 
cooled and light yellow colored spongy solid separated. The 
obtained solid was filtered and purified by recrystallization 
from DMF to afford compounds 3a–f. 
 
(E)-9-ethyl-N-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)-
9H-carbazol-3-amine (3a) Yellow colored solid; Yield (71 %); 
m.p. 124–125 °C; IR ν͂max /cm–1: 3060 (=CH), 1599 (–CH=N), 
1504 (C=C); 1H NMR (CDCl3) δ /ppm: 1.42 (t, 3H, J=7.1 Hz, 
CH3), 4.41 (q, 2H, J=7.1 Hz, N–CH2), 7.20–7.26 (m, 1H, ArH), 
7.30–7.35 (m, 1H, ArH), 7.41–7.48 (m, 3H, ArH), 7.50–7.55 
(m, 5H, ArH), 7.60–7.75 (m, 5H, ArH), 7.85–8.10 (m, 2H, 
ArH), 8.75 (s, 1H, –CH=N), 8.89 (s, 1H, pyrazole ring); 13C 
NMR (CDCl3) δ/ppm: 13.80, 37.75, 108.71, 108.80, 112.38, 
118.83, 119.42, 119.71, 120.65, 120.73, 122.98, 123.55, 
125.99, 127.38, 127.50, 129.64, 130.42, 131.45, 131.90, 




yl)methylene)-9H-carbazol-3-amine (3b) Yellow colored 
solid; Yield (67 %); m.p. 116–117 °C; IR ν͂max /cm–1: 3048 
(=CH), 1596 (–CH=N), 1504 (C=C), 1216 (Ar–F); 1H NMR 
(CDCl3) δ/ ppm: 1.42 (t, 3H, J =7.0 Hz, CH3), 4.42 (q, 2H, 
J=7.0 Hz, N–CH2), 7.20–7.29 (m, 1H, ArH), 7.38–7.45 (m, 
1H, ArH), 7.49–7.56 (m, 3H, ArH), 7.59–7.75 (m, 4H, ArH), 
7.80–7.95 (m, 4H, ArH), 7.99–8.20 (m, 3H, ArH), 8.68 (s, 1H, 
–CH=N), 8.75 (s, 1H, pyrazole ring); 13C NMR (CDCl3) δ/ppm: 
13.85, 37.70, 108.72, 108.85, 112.49, 118.90, 119.47, 119.70, 
120.68, 120.79, 122.95, 123.59, 125.90, 127.36, 127.50, 
129.60, 130.45, 131.47, 131.90, 138.70, 139.53, 140.55, 
143.92, 150.10, 152.66; MS (m/z): 459.10 (M+H)+. 
 
(E)-N-((3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)methyl-
ene)-9-ethyl-9H-carbazol-3-amine (3c) Yellow colored solid; 
Yield (70 %); m.p. 138–139 °C; IR ν͂max /cm–1: 3048 (=CH), 
1598 (–CH=N), 1503 (C=C), 1089 (Ar–Cl); 1H NMR (CDCl3) 
δ/ppm: 1.44 (t, 3H, J=7.1 Hz, CH3), 4.37 (q, 2H, J=7.1 Hz,  
N–CH2), 7.21–7.34 (m, 2H, ArH), 7.36–7.50 (m, 3H, ArH), 
7.52–7.77 (m, 5H, ArH), 7.81–7.85 (m, 4H, ArH), 7.89–8.13 
(m, 2H, ArH), 8.65 (s, 1H, –CH=N), 8.71(s, 1H, pyrazole ring); 
13C NMR (CDCl3) δ/ ppm: 13.84, 37.70, 108.69, 108.85, 
112.36, 118.90, 119.37, 119.70, 120.58, 120.64, 122.94, 
123.50, 125.96, 127.31, 127.57, 128.97, 129.59, 130.11, 
134.71, 138.72, 139.46, 140.53, 143.91, 150.14, 152.51, 
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ene)-9-ethyl-9H-carbazol-3-amine (3d) Yellow colored solid; 
Yield (68 %); m.p. 130–131 °C; IR ν͂max /cm–1: 3051 (=CH), 
1598 (–CH=N), 1504 (C=C), 698 (Ar–Br); 1H NMR (CDCl3) 
δ/ppm: 1.44 (t, 3H, J=7.1 Hz, CH3), 4.38 (q, 2H, J=7.1 Hz,  
N–CH2), 7.21–7.25 (m, 1H, ArH), 7.34–7.37 (m, 1H, ArH), 
7.41–7.46 (m, 3H, ArH), 7.49–7.55 (m, 3H, ArH), 7.62–7.77 
(m, 4H, ArH), 7. 83–7.85 (m, 2H, ArH), 7.95–8.10 (m, 2H, 
ArH), 8.65 (s, 1H, –CH=N), 8.96 (s, 1H, pyrazole ring); 13C 
NMR (CDCl3) δ/ppm: 13.88, 37.73, 108.70, 108.85, 112.39, 
118.93, 119.40, 119.74, 120.63, 120.70, 122.99, 123.54, 
125.98, 127.34, 127.55, 129.62, 130.41, 131.46, 131.95, 




ene)-9H-carbazol-3-amine (3e) Yellow colored solid; Yield 
(70 %); m.p. 122–123 °C; IR ν͂max /cm–1: 3051 (=CH), 1598 
(–CH=N), 1531 (C=C); 1H NMR (CDCl3) δ/ ppm: 1.39 (t, 3H, 
J=7.1 Hz, CH3), 2.30 (s, 3H, ArCH3), 4.44 (q, 2H, J=7.1 Hz,  
N–CH2), 7.20–7.27 (m, 2H, ArH), 7.42–7.50 (m, 3H, ArH), 
7.55–7.69 (m, 5H, ArH), 8.03–8.12 (m, 4H, ArH), 8.18–8.28 
(m, 2H, ArH), 8.89 (s, 1H, –CH=N), 9.17 (s, 1H, pyrazole ring); 
13C NMR (CDCl3) δ /ppm: 13.84, 20.89, 37.78, 108.65, 
108.88, 112.40, 118.92, 119.36, 119.72, 119.80, 120.46, 
120.73, 123.13, 123.58, 125.97, 126.50, 127.10, 127.38, 
127.67, 127.70, 129.68, 134.40, 138.70, 139.39, 140.58, 
144.60, 147.68, 150.18; MS (m/z): 455.08 (M+H)+. 
 
(E)-9-ethyl-N-((1-phenyl-3-(thiophen-2-yl)-1H-pyrazol-4-
yl)methylene)-9H-carbazol-3-amine (3f) Yellow colored 
solid; Yield (72 %); m.p. 109–110 °C; IR ν͂max /cm–1: 3054 
(=CH), 1597 (–CH=N), 1510 (C=C), 1185 (C–S);1H NMR 
(CDCl3) δ/ ppm: 1.34 (t, 3H, J =7.1 Hz, CH3), 4.45 (q, 2H, 
J=7.1 Hz, N–CH2), 7.19–7.23 (m, 2H, ArH), 7.40–7.51 (m, 
3H, thiophenen ring), 7.57–7.69 (m, 5H, ArH), 8.00–8.10 (m, 
3H, ArH), 8.16–8.24 (m, 2H, ArH), 8.88 (s, 1H, –CH=N), 9.15 
(s, 1H, pyrazole ring); 13C NMR (CDCl3) δ/ ppm: 13.88, 37.74, 
108.69, 108.85, 112.43, 118.91, 119.37, 119.71, 119.82, 
120.51, 120.63, 123.03, 123.56, 125.96, 126.51, 127.15, 
127.28, 127.65, 127.75, 129.58, 134.42, 138.75, 139.38, 
140.56, 144.10, 147.69, 150.14; MS (m/z): 447.16 (M+H)+. 
 
General Procedure for the Synthesis of Compounds 5a-f 
Substituted phenylisothiocynate 4 (1 mmol) was added 
dropwise to a well stirred solution of 9-ethyl-9H-carbazol-
3-amine 1 (1 mmol) in ethanol (5 mL), with constant stirring. 
A light yellow colored solid precipitated, which after 30 min 
was filtered off and crude compounds were recrystallized 
from ethanol to afford the target compounds 5a–f. 
 
1-(9-ethyl-9H-carbazol-6-yl)-3-phenylthiourea (5a) Light 
yellow colored solid; Yield (68 %); m.p. 158–159 °C; IR 
ν͂max /cm–1: 3357 (NH), 3173 (NH), 2965 (=CH), 1534 (C=S); 
1H NMR (CDCl3) δ/ ppm: 1.33(t, 3H, J=6.2 Hz, CH3), 4.45  
(q, 2H, J=6.7 Hz, N–CH2), 7.12–7.22 (m, 4H, ArH), 7.33–7.36 
(m, 4H, ArH), 7.45–7.54 (m, 2H, ArH), 7.59–8.15(m, 2H, 
ArH), 9.65 (s, 1H, NH), 9.81 (s, 1H, NH); 13C NMR (CDCl3) 
δ/ppm: 13.87, 37.78, 108.87, 109.40, 118.79, 119.39, 
120.76, 122.37, 123.62, 124.45, 125.18, 126.52, 126.63, 
127.68, 129.24, 137.76, 138.99, 140.58, 180.76; MS (m/z): 
346.13 (M+H)+. 
 
1-(9-ethyl-9H-carbazol-6-yl)-3-(4-fluorophenyl) thiourea (5b) 
Light yellow colored solid; Yield (65 %); m.p. 161–162 °C; IR 
ν͂max /cm–1: 3366 (NH), 3183 (NH), 2964 (=CH), 1530 (C=S); 
1H NMR (CDCl3) δ/ ppm: 1.44(t, 3H, J=7.0 Hz, CH3), 4.44 (q, 
2H, J=6.7 Hz, N–CH2), 7.15–7.17 (m, 1H, ArH), 7.20–7.28 
(m, 2H, ArH), 7.32–7.37 (m, 1H, ArH), 7.40–7.45 (m, 3H, 
ArH), 7.48–7.53 (m, 3H, ArH), 7.56–7.65 (m, 1H, ArH), 8.07 
(s, 1H, NH), 8.21 (s, 1H, NH); 13C NMR (CDCl3) δ/ ppm: 14.28, 
37.76, 110.22, 110.29, 117.30, 120.33, 121.14, 122.47, 
122.75, 122.99, 123.15, 123.25, 123.91, 125.73, 127.00, 
128.38, 129.11, 135.44, 140.65, 142.21, 149.72, 157.45, 
192.98; MS (m/z): 364.15 (M+H)+. 
 
1-(4-chlorophenyl)-3-(9-ethyl-9H-carbazol-6-yl) thiourea (5c) 
Light yellow colored solid; Yield (69 %), m.p. 121–122 °C; IR 
ν͂max /cm–1: 3321 (NH), 3120 (NH), 2973 (=CH), 1529 (C=S); 
1H NMR (CDCl3) δ/ ppm: 1.33(t, 3H, J=6.2 Hz, CH3), 4.47  
(q, 2H, J=6.7 Hz, N–CH2), 7.16–7.22 (m, 3H, ArH), 7.33–7.37 
(m, 3H, ArH), 7.43–7.49 (m, 3H, ArH), 7.60–8.17 (m, 2H, ArH), 
9.75 (s, 1H, NH), 9.99 (s, 1H, NH); 13C NMR (CDCl3) δ/ppm: 
13.87, 37.82, 108.96, 109.69, 118.94, 119.56, 120.78, 122.24, 
123.01, 123.83, 124.34, 124.86, 126.35, 126.76, 129.86, 
134.43, 139.19, 140.63, 180.63; MS (m/z): 380.04 (M+H)+. 
 
1-(4-bromophenyl)-3-(9-ethyl-9H-carbazol-6-yl)thiourea (5d) 
Light yellow colored solid; Yield (65 %); m.p. 132–133 °C; IR 
ν͂max /cm–1: 3330 (NH), 3128 (NH), 2975 (=CH), 1525 (C=S); 
1H NMR (CDCl3) δ/ppm: 1.34 (t, 3H, J=6.4 Hz, CH3), 4.45 (q, 
2H, J=6.8 Hz, N–CH2), 7.18–7.25 (m, 3H, ArH), 7.32–7.39 
(m, 3H, ArH), 7.45–7.55 (m, 3H, ArH), 7.65–8.10 (m, 2H, 
ArH), 9.60 (s, 1H, NH), 9.70 (s, 1H, NH); 13C NMR (CDCl3) 
δ/ppm: 13.82, 37.79, 108.84, 109.65, 118.90, 119.55, 
120.70, 122.22, 123.20,123.85, 124.38, 124.89, 126.32, 
126.75, 129.85, 134.40, 139.29, 140.53, 180.60; MS (m/z): 
424.10(M+H)+. 
 
1-(9-ethyl-9H-carbazol-6-yl)-3-p-tolylthiourea (5f) Light 
yellow colored solid; Yield (65 %); m.p. 143–144 °C; IR 
ν͂max /cm–1: 3366 (NH), 3179 (NH), 2970 (=CH), 1531 (C=S); 
1H NMR (CDCl3) δ /ppm: 1.44 (t, 3H, J=6.3 Hz, CH3), 2.34 (s, 
3H, ArCH3), 4.35 (q, 2H, J=6.3 Hz, N–CH2), 7.18–7.29 (m, 2H, 
ArH), 7.34–7.48 (m, 2H, ArH), 7.52–7.69 (m, 5H, ArH), 7.75–
7.95 (m, 2H, ArH), 8.05 (s, 1H, NH), 8.25 (s, 1H, NH); 13C 
NMR (CDCl3) δ/ppm: 13.81, 37.89, 108.84, 109.68, 118.92, 
119.79, 120.59, 122.28, 123.35, 123.80, 124.39, 124.84, 
126.38, 126.64, 129.70, 135.48, 139.39, 140.75, 180.69; MS 
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